Glivec (Imatinib): Extend survival for your Ph+ CML and KIT+ GIST patients

About Glivec

Target: CML

Target: GIST

Rare Diseases

For Your Patients

News and Events

Resources

European Summary of Product Characteristics

Learn more about Glivec's cutting edge molecularly-targeted treatment mechanism and its application in CML and GIST treatment regimens.

Find out how Glivec is transforming the management and treatment of certain cancers, including CML and GIST.

The international patient assistance programme, GIPAP is open in about 80 countries. As of November 30, 2007 the total number of patients reached was 19,378.

Help us improve Glivec.com.
Please take our short survey.



	Positive results prompt US National Cancer Institute to make Glivec available to patients in post-surgical GIST study Hassan I, et al.



	Hassan I, et al. Surgically Managed Gastrointestinal Stromal Tumours (GIST): A Comparative and Prognostic Analysis. Annals of Surgical Oncology 2008 Jan



	World Congress Gastro Intestinal Cancer. June 25-28, 2008 Barcelona, Spain.
	European Society of Clinical Oncology Conference (ESMO) July 3-6, 2008 Lugano, Switzerland.

Our weekly newsletter keeps you informed of the latest haematology news and oncology news.

Disclaimer: This is an international website for Glivec (imatinib) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the For US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.